Safe introduction of warfarin for thrombotic prophylaxis in atrial fibrillation requiring only a weekly INR

Clinical and Laboratory Haematology

Volumn 26, Issue 1, 2004, Pages 43-47

  Janes, S ^a   Challis, R ^a   Fisher, F ^a  

^a ST RICHARD S HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Atrial fibrillation; Clinical studies; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT INDICATION; WORKLOAD;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; THROMBOSIS; TIME FACTORS; WARFARIN;

EID: 1242340266     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0141-9854.2003.00579.x     Document Type: Article

References (3)

1. Haemostasis and Thrombosis Task Force (1998) Guidelines for oral anticoagulation (3rd edn). British Journal of Haematology 101, 374-387.
2. Laupacis A., Albers G.W., Dalen J.E., Dunn M.I., Jacobson A.K. & Singer D.E. (1998) Antithrombotic therapy in atrial fibrillation. Chest 114, 590S-599S.
3. Lidstone A., Janes S.L. & Stross P. (2000) INR: intervals of measurement can safely extend to 14 weeks. Clinical and Laboratory Haematology 22, 291-293.